Annals of Oncology 10:421-425, 1999
© 1999 European Society for Medical Oncology
research-article |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype
1Department of Medicine, Institut Gustave Roussy
2FSMIT, Hópital Paul Brousse Villejuif, France
3Hospital 12th October Madrid, Spain
Correspondence to: Eric Raymond, MD., Department of Medicine, Institut Gustave Roussy, 94805, Villejuif, France. E-mail : erigr{at}aol.com
Background: This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT).
Patients and methods: Between July 1989 and December 1991, 44 consecutive patients (M/F 36/8; median age: 45, range 20–72; performance status (PS) 0: 20 patients, PS 1: 14 patients, PS 2: 10 patients) with recurrent or metastatic UCNT were entered in this study after complete clinical, biological, and radiological pre-therapeutic work-ups. Chemotherapy (FMEP regimen) consisted of 800 mg/m2/day 5-fluorouracil in continuous infusion from day 1 to day 4 combined with 70 mg/m2 epirubicin, 10 mg/m2 mitomycin, and 100 mg/m2 cisplatin on day 1, every four weeks for six cycles. Mitomycin was delivered in cycles 1, 3, and 5 only. Eleven patients had isolated loco-regional recurrences, 12 patients had local recurrences associated with distant metastasis, and 21 patients had metastasis only. Toxicity and response were evaluated according to WHO criteria.
chemotherapy, mitomycin, recurrent, undifferentiated carcinoma of nasopharyngeal type
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Licitra, P. Bossi, L. D. Locati, and C. Bergamini Is Restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer? J. Clin. Oncol., October 20, 2005; 23(30): 7757 - 7758. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Lin, J.-S. Jan, C.-Y. Hsu, W.-M. Liang, R.-S. Jiang, and W.-Y. Wang Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival J. Clin. Oncol., February 15, 2003; 21(4): 631 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. C. Ngan, H. H. Y. Yiu, W. H. Lau, S. Yau, F. Y. Cheung, T. M. Chan, C. H. Kwok, C. Y. Chiu, S. K. Au, W. Foo, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study Ann. Onc., August 1, 2002; 13(8): 1252 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-F. Foo, E.-H. Tan, S.-S. Leong, J. T. S. Wee, T. Tan, K.-W. Fong, L. Koh, B.-C. Tai, L.-G. Lian, and D. Machin Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type Ann. Onc., January 19, 2002; 13(1): 150 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-L. Hong, L.-L. Ting, J.-Y. Ko, M.-M. Hsu, T.-S. Sheen, P.-J. Lou, C.-C. Wang, N.-N. Chung, and L. T. Lui Induction Chemotherapy With Mitomycin, Epirubicin, Cisplatin, Fluorouracil, and Leucovorin Followed by Radiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma J. Clin. Oncol., December 1, 2001; 19(23): 4305 - 4313. [Abstract] [Full Text]
|
|
|
|
|
|
A. Fandi, M. Bachouchi, N. Azli, A. Taamma, H. Boussen, P. Wibault, F. Eschwege, J.-P. Armand, J. Simon, and E. Cvitkovic Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type J. Clin. Oncol., March 13, 2000; 18(6): 1324 - 1330. [Abstract] [Full Text] [PDF]
|
|